Posting Date: May 3, 2021

Closing Date: May 13, 2021 11:30 a.m.

ET Reference Number: 21-032743

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Laboratory Testing

The Surgery Branch of the National Cancer Institute is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Efforts run the gamut from basic studies of cancer immunology to the conduct of clinical immunotherapy trials for patients with metastatic cancer. The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The National Cancer Institute plans to purchase Certification Laboratory Testing Services for In-Vitro from Indiana University. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on May 13, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The Indiana University Gene Therapy Testing Laboratory (IU GTTL) is a well-established core laboratory within the Indiana University School of Medicine and the Department of Medical and Molecular Genetics and is dedicated to the development, production and testing of gene therapy technology. The IU GTTL offers a wide variety of routine and specialized assays important in safety testing and certifying both clinical and non-clinical grade vectors. FACS, PCR and quantitative PCR, and S+L- assays are available to accommodate a wide variety of vector constructs. Quantitative PCR is also available to measure transduction efficiency *in vitro* and *in vivo*. The Surgery Branch/NCI does not have the necessary components to perform the required RCR testing nor personnel trained in the implementation and interpretation of RCR PCR and S+L- assays. The IU GTTL has a proven performance record in providing RCR testing services and does so in a timely manner and in consultation with Surgery Branch staff.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request